Wednesday, July 2, 2014

Azithromycin- Preferred Treatment for Meibomian Gland Dysfunction.

New Research IndicatesAzithromycin is more effective than Doxycycline for Meibomian Gland Dysfunction and Blepharitis.
There are several studies concerning the use of topical azithromycin in ocular surface diseases. 
New research at the University of Louisville compared the effectiveness of topical azithromycin versus oral doxycycline therapy in meibomian gland dysfunction (and  Blepharitis) Twenty-two (22) subjects were treated with topical azithromucin solution for one month and seven subjects were treated with oral doxycycline for two (20 months. The study concluded that while both topical azithromycin and oral doxycycline improved clinical signs and symptoms of meibomian gland dysfunction, the "response to azithromycin is more rapid and more robust than doxycycline."
Another research study from the Ohio State University evaluated the efficacy of a four-week treatment with topical 1.0% azithromycin solution versus rewetting drops in patients with contact lens related dry eye.  Patients are able to wear contact lenses two-hours longer  throughout the four-week study period when azithromycin solution was use.
Blepharitis being a chronic inflammation of the eye lid goes hand in hand with Meibomian Gland Dysfunction and chronic dry eyes. Here is how TheraLife Eye can help!
How can TheraLife Eye Help?
TheraLife Eye is uniquely formulated to restore normal cell functions to tear secretion glands intra-cellularly for sustainable, long lasting relief. Clinically proven to work for 80% of first time users.  Antibiotics help reduce inflammation, however, inflammation shuts down tear secretion glands.  Use TheraLife Eye to restore normal tear function. 
 
Call us toll free 1-877-917-1989
International (650) 949-6080
Send inquiries to: info@theralife.com
Follow us at twitter and facebook

REFERENCES
1. Berman BM, Langevin HM, Witt CM, et al. Acupuncture for Chronic Low Back Pain. N Engl J Med 2010; 363:454-461.
2. Cassileth BR, Deng GE, Gomez JE, et al. Complementary therapies and integrative oncology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd ed). Chest 2007;132(3 Suppl):340S-354S.
3. Li S, Yu B, Zhou D, et al. Acupuncture for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2011 Apr 13;4:CD007839.
4. Shaw KS, Bower KS, Mines MJ,et al. Does acupuncture treatment benefit dry eye? Invest Ophthalmol Vis Sci 2011; 52 (6): E-abstract 3839.
5. Hom MM. False staining appearance with lissamine green. Invest Ophthalmol Vis Sci 2011; 52 (6): E-abstract 1968.
6. Ocasio MA, Galor A, Zheng DD, et al. Trends in dry eye medication use and expenditures: Medical expenditure panel survey 2001 - 2006. Invest Ophthalmol Vis Sci 2011; 52 (6): E-abstract 5529.
7. Chi SL, Acquah K, Richard MJ, et al. Relation between punctual plug usage and reimbursement amongst medicare beneficiaries. Invest Ophthalmol Vis Sci 2011; 52 (6): E-abstract 3852.
8. Mudgil P. Effect of hyperosmolarity on the antimicrobial properties of tear proteins. Invest Ophthalmol Vis Sci 2011; 52 (6): E-abstract 1486.
9. Foulks GN, Borchman D, Yappert MC. Comparative effectiveness of azithromycin and doxycycline in therapy of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2011; 52 (6): E-abstract 3816.
10. Bickle KM, Nichols KK, Haque R, et al. Efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye. Invest Ophthalmol Vis Sci 2011; 52 (6): E-abstract 3842.
11. Senba K, Miyamoto T, Eguchi H, et al. The efficacy of oral pilocarpine for the treatment of dry eye symptoms in patients with aqueous tear deficiency and evaporative dry eye. Invest Ophthalmol Vis Sci 2011; 52 (6): E-abstract 3837.
12. Miyamoto T, Eguchi H, Mitamura Y. An original administration of oral pilocarpine (Salagen tablet 5 mg) for dry eye. Invest Ophthalmol Vis Sci 2011; 52 (6): E-abstract 3835.
13. Labbe A, Brasnu E, Van Went C, et al. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2011; 52 (6): E-abstract 218.
14. VanWent C, Alalwani H, Brasnu E, et al. Corneal sensitivity in patients treated for glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 201

No comments:

Post a Comment